Table 3.

Quality of life, assessed by the SF-12v2.

SF-12v2	Experimental		Control		Adjusted difference (95% CI)b
	Mean ± SD	P-valuea	Mean ± SD	P-valuea
PF
Baseline	50.40 ± 9.56		53.42 ± 6.12
Week 4	54.64 ± 4.96	0.237	52.82 ± 6.90	0.673	−4.84 (−12.65–2.97)
RP
Baseline	52.25 ± 6.72		52.27 ± 7.57
Week 4	55.18 ± 5.07	0.133	50.30 ± 7.99	0.485	−4.90 (−11.68–1.88)
BP
Baseline	51.49 ± 10.00		53.57 ± 5.96
Week 4	55.65 ± 3.96	0.165	51.49 ± 7.71	0.337	−6.24 (−13.47–0.99)
GH
Baseline	53.72 ± 8.32		45.00 ± 10.60
Week 4	56.62 ± 4.27	0.193	43.16 ± 10.28	0.553	−4.74 (−12.32–2.84)
VT
Baseline	61.17 ± 7.13		54.36 ± 11.79
Week 4	63.44 ± 6.49	0.190	50.58 ± 10.51	0.337	−6.05 (−14.78–2.67)
SF
Baseline	51.43 ± 7.74		49.38 ± 8.78
Week 4	53.48 ± 5.78	0.387	48.01 ± 10.27	0.739	−3.42 (−12.95–6.10)
RE
Baseline	52.68 ± 5.36		49.08 ± 7.51
Week 4	49.08 ± 9.85	0.145	47.09 ± 8.26	0.514	1.60 (−6.17–9.37)
MH
Baseline	54.06 ± 8.49		47.44 ± 11.82
Week 4	55.38 ± 9.25	0.598	43.47 ± 10.08	0.201	−5.29 (−13.17–2.58)
PCS
Baseline	51.52 ± 6.93		52.89 ± 6.00
Week 4	56.58 ± 3.20	0.024∗	52.10 ± 6.38	0.633	−5.85 (-11.07∼-0.62)∗
MCS
Baseline	55.44 ± 7.48		47.92 ± 8.63
Week 4	55.50 ± 11.35	0.980	44.44 ± 8.25	0.189	−3.54 (−10.56–3.47)

∗p < 0.05.

Abbreviations: SD: standard deviation; SF-12v2: Short Form Health Survey-12v2; PF: physical functioning; RP: role limitations due to physical problems; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitations due to emotional problems; MH: general mental health; PCS: physical component summary measures; MCS: mental component summary measures.

^aRepeated measures ANOVA.

^bIndependent t-test was used for the statistical analysis of changes from baseline in each outcome between two groups.